Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2015

01.01.2015 | Epidemiology

Immunoassay and Nb2 lymphoma bioassay prolactin levels and mammographic density in premenopausal and postmenopausal women the Nurses’ Health Studies

verfasst von: Megan S. Rice, Shelley S. Tworoger, Kimberly A. Bertrand, Susan E. Hankinson, Bernard A. Rosner, Yvonne B. Feeney, Charles V. Clevenger, Rulla M. Tamimi

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Higher circulating prolactin levels have been associated with higher percent mammographic density among postmenopausal women in some, but not all studies. However, few studies have examined associations with dense area and non-dense breast area breast or considered associations with prolactin Nb2 lymphoma cell bioassay levels. We conducted a cross-sectional study among 1,124 premenopausal and 890 postmenopausal women who were controls in breast cancer case–control studies nested in the Nurses’ Health Study (NHS) and NHSII. Participants provided blood samples in 1989–1990 (NHS) or 1996–1999 (NHSII) and mammograms were obtained from around the time of blood draw. Multivariable linear models were used to assess the associations between prolactin levels (measured by immunoassay or bioassay) with percent density, dense area, and non-dense area. Among 1,124 premenopausal women, percent density, dense area, and non-dense area were not associated with prolactin immunoassay levels in multivariable models (p trends = 0.10, 0.18, and 0.69, respectively). Among 890 postmenopausal women, those with prolactin immunoassay levels in the highest versus lowest quartile had modestly, though significantly, higher percent density (difference = 3.01 percentage points, 95 % CI 0.22, 5.80) as well as lower non-dense area (p trend = 0.02). Among women with both immunoassay and bioassay levels, there were no consistent differences in the associations with percent density between bioassay and immunoassay levels. Postmenopausal women with prolactin immunoassay levels in the highest quartile had significantly higher percent density as well as lower non-dense area compared to those in the lowest quartile. Future studies should examine the underlying biologic mechanisms, particularly for non-dense area.
Literatur
1.
Zurück zum Zitat Byrne C et al (1995) Mammographic features and breast cancer risk: effects with time, age, and menopause status. J Natl Cancer Inst 87(21):1622–1629PubMedCrossRef Byrne C et al (1995) Mammographic features and breast cancer risk: effects with time, age, and menopause status. J Natl Cancer Inst 87(21):1622–1629PubMedCrossRef
2.
Zurück zum Zitat Boyd NF et al (1995) Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Inst 87(9):670–675PubMedCrossRef Boyd NF et al (1995) Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Inst 87(9):670–675PubMedCrossRef
3.
Zurück zum Zitat Tworoger SS, Hankinson SE (2008) Prolactin and breast cancer etiology: an epidemiologic perspective. J Mammary Gland Biol Neoplasia 13(1):41–53PubMedCrossRef Tworoger SS, Hankinson SE (2008) Prolactin and breast cancer etiology: an epidemiologic perspective. J Mammary Gland Biol Neoplasia 13(1):41–53PubMedCrossRef
5.
Zurück zum Zitat Greendale GA et al (2007) Serum prolactin levels are positively associated with mammographic density in postmenopausal women. Breast Cancer Res Treat 105(3):337–346PubMedCrossRef Greendale GA et al (2007) Serum prolactin levels are positively associated with mammographic density in postmenopausal women. Breast Cancer Res Treat 105(3):337–346PubMedCrossRef
6.
Zurück zum Zitat Bremnes Y et al (2007) Endogenous sex hormones, prolactin and mammographic density in postmenopausal Norwegian women. Int J Cancer 121(11):2506–2511PubMedCrossRef Bremnes Y et al (2007) Endogenous sex hormones, prolactin and mammographic density in postmenopausal Norwegian women. Int J Cancer 121(11):2506–2511PubMedCrossRef
7.
Zurück zum Zitat Maskarinec G et al (2007) IGF-I and mammographic density in four geographic locations: a pooled analysis. Int J Cancer 121(8):1786–1792PubMedCrossRef Maskarinec G et al (2007) IGF-I and mammographic density in four geographic locations: a pooled analysis. Int J Cancer 121(8):1786–1792PubMedCrossRef
8.
Zurück zum Zitat Tamimi RM et al (2005) Endogenous sex hormone levels and mammographic density among postmenopausal women. Cancer Epidemiol Biomark Prev. 14(11 Pt 1):2641–2647CrossRef Tamimi RM et al (2005) Endogenous sex hormone levels and mammographic density among postmenopausal women. Cancer Epidemiol Biomark Prev. 14(11 Pt 1):2641–2647CrossRef
9.
Zurück zum Zitat Walker K et al (2009) Premenopausal mammographic density in relation to cyclic variations in endogenous sex hormone levels, prolactin, and insulin-like growth factors. Cancer Res 69(16):6490–6499PubMedCrossRef Walker K et al (2009) Premenopausal mammographic density in relation to cyclic variations in endogenous sex hormone levels, prolactin, and insulin-like growth factors. Cancer Res 69(16):6490–6499PubMedCrossRef
10.
Zurück zum Zitat McCormack VA et al (2009) Sex steroids, growth factors and mammographic density: a cross-sectional study of UK postmenopausal Caucasian and Afro-Caribbean women. Breast Cancer Res 11(3):R38PubMedCentralPubMedCrossRef McCormack VA et al (2009) Sex steroids, growth factors and mammographic density: a cross-sectional study of UK postmenopausal Caucasian and Afro-Caribbean women. Breast Cancer Res 11(3):R38PubMedCentralPubMedCrossRef
13.
Zurück zum Zitat Hoffmann T, Penel C, Ronin C (1993) Glycosylation of human prolactin regulates hormone bioactivity and metabolic clearance. J Endocrinol Invest 16(10):807–816PubMedCrossRef Hoffmann T, Penel C, Ronin C (1993) Glycosylation of human prolactin regulates hormone bioactivity and metabolic clearance. J Endocrinol Invest 16(10):807–816PubMedCrossRef
14.
Zurück zum Zitat Sinha YN (1995) Structural variants of prolactin: occurrence and physiological significance. Endocr Rev 16(3):354–369PubMedCrossRef Sinha YN (1995) Structural variants of prolactin: occurrence and physiological significance. Endocr Rev 16(3):354–369PubMedCrossRef
15.
Zurück zum Zitat Gout PW, Beer CT, Noble RL (1980) Prolactin-stimulated growth of cell cultures established from malignant Nb rat lymphomas. Cancer Res 40(7):2433–2436PubMed Gout PW, Beer CT, Noble RL (1980) Prolactin-stimulated growth of cell cultures established from malignant Nb rat lymphomas. Cancer Res 40(7):2433–2436PubMed
16.
Zurück zum Zitat Tworoger, S.S., et al., (2014) Bioactive prolactin levels and risk of breast cancer: a nested case–control study. Cancer Epidemiol Biomark Prev Tworoger, S.S., et al., (2014) Bioactive prolactin levels and risk of breast cancer: a nested case–control study. Cancer Epidemiol Biomark Prev
17.
Zurück zum Zitat Schernhammer ES et al (2005) Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk. Cancer Epidemiol Biomark Prev 14(3):699–704CrossRef Schernhammer ES et al (2005) Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk. Cancer Epidemiol Biomark Prev 14(3):699–704CrossRef
18.
Zurück zum Zitat Tworoger SS, Sluss P, Hankinson SE (2006) Association between plasma prolactin concentrations and risk of breast cancer among predominately premenopausal women. Cancer Res 66(4):2476–2482PubMedCrossRef Tworoger SS, Sluss P, Hankinson SE (2006) Association between plasma prolactin concentrations and risk of breast cancer among predominately premenopausal women. Cancer Res 66(4):2476–2482PubMedCrossRef
19.
Zurück zum Zitat Schernhammer ES, Hankinson SE (2009) Urinary melatonin levels and postmenopausal breast cancer risk in the Nurses’ Health Study cohort. Cancer Epidemiol Biomark Prev 18(1):74–79CrossRef Schernhammer ES, Hankinson SE (2009) Urinary melatonin levels and postmenopausal breast cancer risk in the Nurses’ Health Study cohort. Cancer Epidemiol Biomark Prev 18(1):74–79CrossRef
20.
Zurück zum Zitat Hankinson SE et al (1998) Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351(9113):1393–1396PubMedCrossRef Hankinson SE et al (1998) Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351(9113):1393–1396PubMedCrossRef
21.
Zurück zum Zitat Schernhammer ES et al (2006) Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II. Endocr Relat Cancer 13(2):583–592PubMedCrossRef Schernhammer ES et al (2006) Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II. Endocr Relat Cancer 13(2):583–592PubMedCrossRef
22.
Zurück zum Zitat Rosner B (1983) Percentage points for a generalized ESD many-outlier procedure. Technometrics 25:165–172CrossRef Rosner B (1983) Percentage points for a generalized ESD many-outlier procedure. Technometrics 25:165–172CrossRef
23.
Zurück zum Zitat Clevenger CV et al (1995) Expression of prolactin and prolactin receptor in human breast carcinoma. Evidence for an autocrine/paracrine loop. Am J Pathol 146(3):695–705PubMedCentralPubMed Clevenger CV et al (1995) Expression of prolactin and prolactin receptor in human breast carcinoma. Evidence for an autocrine/paracrine loop. Am J Pathol 146(3):695–705PubMedCentralPubMed
24.
Zurück zum Zitat Rosner B et al (2008) Determination of blood pressure percentiles in normal-weight children: some methodological issues. Am J Epidemiol 167(6):653–666PubMedCrossRef Rosner B et al (2008) Determination of blood pressure percentiles in normal-weight children: some methodological issues. Am J Epidemiol 167(6):653–666PubMedCrossRef
25.
Zurück zum Zitat Tamimi RM et al (2005) Endogenous sex hormone levels and mammographic density among postmenopausal women. Cancer Epidemiol Biomark Prev 14(11):2641–2647CrossRef Tamimi RM et al (2005) Endogenous sex hormone levels and mammographic density among postmenopausal women. Cancer Epidemiol Biomark Prev 14(11):2641–2647CrossRef
26.
Zurück zum Zitat Emerman JT et al (1985) Elevated growth hormone levels in sera from breast cancer patients. Horm Metab Res 17(8):421–424PubMedCrossRef Emerman JT et al (1985) Elevated growth hormone levels in sera from breast cancer patients. Horm Metab Res 17(8):421–424PubMedCrossRef
27.
Zurück zum Zitat Maddox PR, Jones DL, Mansel RE (1992) Prolactin and total lactogenic hormone measured by microbioassay and immunoassay in breast cancer. Br J Cancer 65(3):456–460PubMedCentralPubMedCrossRef Maddox PR, Jones DL, Mansel RE (1992) Prolactin and total lactogenic hormone measured by microbioassay and immunoassay in breast cancer. Br J Cancer 65(3):456–460PubMedCentralPubMedCrossRef
28.
Zurück zum Zitat Missmer SA et al (2006) Reproducibility of plasma steroid hormones, prolactin, and insulin-like growth factor levels among premenopausal women over a 2- to 3-year period. Cancer Epidemiol Biomark Prev 15(5):972–978CrossRef Missmer SA et al (2006) Reproducibility of plasma steroid hormones, prolactin, and insulin-like growth factor levels among premenopausal women over a 2- to 3-year period. Cancer Epidemiol Biomark Prev 15(5):972–978CrossRef
29.
Zurück zum Zitat Hankinson SE et al (1995) Reproducibility of plasma hormone levels in postmenopausal women over a 2-3-year period. Cancer Epidemiol Biomark Prev 4(6):649–654 Hankinson SE et al (1995) Reproducibility of plasma hormone levels in postmenopausal women over a 2-3-year period. Cancer Epidemiol Biomark Prev 4(6):649–654
Metadaten
Titel
Immunoassay and Nb2 lymphoma bioassay prolactin levels and mammographic density in premenopausal and postmenopausal women the Nurses’ Health Studies
verfasst von
Megan S. Rice
Shelley S. Tworoger
Kimberly A. Bertrand
Susan E. Hankinson
Bernard A. Rosner
Yvonne B. Feeney
Charles V. Clevenger
Rulla M. Tamimi
Publikationsdatum
01.01.2015
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2015
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-014-3232-z

Weitere Artikel der Ausgabe 1/2015

Breast Cancer Research and Treatment 1/2015 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.